TokenPost·
Pelthos Therapeutics Shares Fall About 35% After Castle Creek Merger Deal
The reported share price was $10.79. The proposed combination would add cell and gene therapies for serious skin diseases to Pelthos’ portfolio.
More news
- TokenPostChoice Hotels' Q3 EPS and Revenue Estimates Rise 9% and 0.1% Year Over Year
- TokenPostFox Q1 Estimates Put Revenue at $4.29 Billion and EPS at $2.02
- TokenPostCNA Financial Q3 Preview Centers on $1.13 Earnings Estimate
- TokenPostVIX Rises Above 20 as U.S. Stocks Sell Off and Risk Aversion Grows
- TokenPostBinance Co-Founder He Yi Pledges More Security After Wallet Theft
- TokenPostThe Bancorp Sets 2027 Core EPS at $7.00-$7.20, Previews 2028 Core EPS